Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,703.55 +456.53 (+0.68%) CMC Crypto 200
1,426.24 -2.33 (-0.16%)
The fight against COVID19
23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The fight against COVID19 | -0.28% | - | - | - |
| ^GSPC | +0.80% | +4.21% | +23.24% | +5574.74% |
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 146.67 | +1.39 | +0.96% | 4:00 pm GMT-4 | 12.59M | 7.70M | 352.99B |
| ABBV | AbbVie Inc. | 161.24 | +4.93 | +3.15% | 4:05 pm GMT-4 | 5.52M | 5.78M | 284.73B |
| PFE | Pfizer Inc. | 28.66 | +0.46 | +1.63% | 4:00 pm GMT-4 | 75.01M | 42.12M | 162.40B |
| SNY | Sanofi | 49.03 | +1.20 | +2.51% | 4:00 pm GMT-4 | 1.78M | 1.98M | 122.55B |
| REGN | Regeneron Pharmaceuticals, Inc. | 980.16 | +10.25 | +1.06% | 4:00 pm GMT-4 | 808.76k | 440.60k | 108.00B |
| GSK | GSK plc | 44.77 | +0.75 | +1.70% | 4:00 pm GMT-4 | 3.62M | 3.12M | 91.29B |
| GILD | Gilead Sciences, Inc. | 64.27 | +0.19 | +0.30% | 4:00 pm GMT-4 | 14.10M | 7.04M | 80.07B |
| MRNA | Moderna, Inc. | 142.55 | -8.94 | -5.90% | 4:00 pm GMT-4 | 7.15M | 4.06M | 54.63B |
| TAK | Takeda Pharmaceutical Company Limited | 13.35 | +0.32 | +2.46% | 4:00 pm GMT-4 | 1.85M | 1.57M | 41.89B |
| BNTX | BioNTech SE | 100.6 | +1.85 | +1.87% | 4:00 pm GMT-4 | 1.56M | 723.66k | 24.24B |
| NVAX | Novavax, Inc. | 15.03 | -0.22 | -1.44% | 4:00 pm GMT-4 | 13.84M | 12.48M | 2.21B |
| VIR | Vir Biotechnology, Inc. | 10.27 | -0.12 | -1.15% | 4:00 pm GMT-4 | 828.23k | 889.63k | 1.40B |
| INO | Inovio Pharmaceuticals, Inc. | 10.13 | +0.36 | +3.68% | 4:00 pm GMT-4 | 254.67k | 427.41k | 262.48M |
Business WireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
COPENHAGEN, Denmark & MAINZ, Germany, June 01, 2024--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab in patients with PDL(1)-positive mNSCLC who had disease progression following one or more prior lines of anti-PD(L)1 containing treatment. The re
Business WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK, June 01, 2024--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and at the 29th European Hematology Association (EHA) Annual Meeting (S225). Th
